SCN9A rs6746030: What Your Genotype Means for Pain Sensitivity
The rs6746030 variant is a common genetic change located within the SCN9A gene, which provides instructions for building a sodium channel involved in pain signaling. Research suggests this variant may influence how individuals perceive pain, though its overall impact remains a subject of ongoing scientific study.
What each genotype means
Increased pain sensitivity
Research suggests that individuals with this genotype may experience increased sensitivity to pain compared to those with the G allele. This association is based on studies of nociceptor excitability, though the clinical impact is considered subtle and may vary significantly between individuals.
The A allele is the minor allele with a frequency of approximately 0.10 to 0.15 in European populations, making this homozygous genotype relatively uncommon.
Moderate pain sensitivity
This genotype is associated with an intermediate influence on pain perception compared to the homozygous states. While some studies have linked the presence of the A allele to increased pain intensity in specific conditions like disc herniation, the overall effect remains limited and should not be used to predict individual pain responses.
This heterozygous genotype is found in a significant portion of the population, consistent with the minor allele frequency of approximately 10-15% in European cohorts.
Typical pain sensitivity
This genotype is considered the common or reference state for this variant and is associated with typical pain perception. There is no evidence to suggest that this genotype confers an altered risk for pain sensitivity compared to the general population.
This is the most common genotype, carried by the majority of individuals in most studied populations.
Understanding the rs6746030 Variant
The rs6746030 variant is a single nucleotide polymorphism (SNP) found within the SCN9A gene. In genetic terms, this means a specific position in the DNA sequence can differ between individuals, with the most common versions being the G allele and the A allele. This specific variant is often referred to as a missense mutation, meaning the change in the DNA code results in a different amino acid being incorporated into the protein structure—specifically, it is known as the R1150W substitution. Because this change occurs in a gene responsible for critical sensory functions, researchers have long been interested in whether this small alteration in the genetic code translates into measurable differences in how people experience physical sensations, particularly pain.
The Role of the SCN9A Gene
The SCN9A gene encodes the alpha subunit of a voltage-gated sodium channel known as NaV1.7. These channels act like tiny gates on the surface of nerve cells, specifically those involved in transmitting pain signals from the body to the brain. When these channels function correctly, they help regulate the electrical impulses that signal pain. Because NaV1.7 is highly concentrated in peripheral neurons, it is considered a primary gatekeeper for nociception, or the sensory nervous system's response to harmful stimuli. When the SCN9A gene is mutated or altered, it can lead to significant changes in channel activity. While some rare, severe mutations in this gene are linked to extreme pain disorders or a complete inability to feel pain, common variants like rs6746030 are thought to have much more subtle effects on the channel's sensitivity.
Research and Evidence Strength
Scientific evidence regarding the impact of rs6746030 on pain perception is currently considered limited and sometimes conflicting. Some studies have suggested that the A allele may be associated with increased NaV1.7 channel activity, potentially leading to lower pain thresholds or higher pain ratings in certain clinical conditions, such as osteoarthritis or sciatica. However, other research, including studies on athletes and pain tolerance, has found no significant differences in pain thresholds between different genotypes. Because pain is a complex experience influenced by many genes, environmental factors, and psychological states, it is difficult to isolate the effect of a single SNP. Consequently, while rs6746030 is a recognized marker in pain research, it is not currently used as a reliable clinical predictor for an individual's personal pain sensitivity.
What This Information Means for You
If you have received information about your rs6746030 genotype, it is important to view it as a piece of scientific data rather than a medical diagnosis. Genetic variants like this are common in the general population and do not determine your ability to feel pain or your risk for chronic pain conditions. Because the evidence linking this variant to specific pain outcomes is not definitive, this information cannot be used to predict how you will respond to injury or medical procedures. If you are concerned about pain management, chronic pain, or how you respond to specific medications, you should always consult with a qualified healthcare provider or pharmacist. They can provide personalized guidance based on your clinical history rather than relying on individual genetic markers.
How common is this variant?
The minor A allele of rs6746030 has a frequency of approximately 0.10 to 0.15 in European populations, though frequencies can vary across different global ancestries.
Frequently asked questions
Does the rs6746030 variant mean I have a high pain tolerance?
No. While some research has explored associations between this variant and pain perception, the evidence is not strong enough to conclude that it determines your personal pain tolerance.
Can I use this genetic information to choose pain medication?
No. You should never use genetic information to make decisions about medication. Always discuss your pain management and medication options with your doctor or pharmacist.
Is rs6746030 linked to chronic pain conditions?
Some studies have looked for links between this variant and conditions like osteoarthritis or back pain, but results have been inconsistent and often show no significant contribution.
Why do different studies show different results for this SNP?
Pain is a complex trait influenced by many genes and environmental factors. Small studies may find different results due to differences in the populations studied, the types of pain measured, and other genetic variables.
Sources & further reading
Educational information only, last refreshed 9/26/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs6746030?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in SCN9A
Variants in SCN9A are linked to autosomal dominant painful channelopathies, including primary erythromelalgia and paroxysmal extreme pain disorder.
A pathogenic variant in SCN9A linked to paroxysmal extreme pain disorder, relevant for carrier screening in hereditary pain syndromes.
This variant in the SCN9A gene is associated with autosomal dominant painful channelopathies, including primary erythromelalgia.